Fig. 5. FGF dose response. (A) Stage 10.5 ectoderm was treated with increasing doses of bFGF (0.08, 0.4, 2, 10, 50, 250, 1250 ng/ml) and then cultured to the early tailbud stage (stage 20). RT-PCR analysis of nrp-1, otx2, En-2, Krox 20, Hox B9, Muscle actin, Collagen type II shows that when stage 10.5 ectoderm is treated with increasing amounts of bFGF, nrp-1 expression increases. At 2 ng/ml Hox B9 and 10 ng/ml Krox 20 are induced, while En-2 or otx2 is not induced by any dose, and the low level expression of otx2 seen in untreated explants is repressed by 0.4 ng/ml or more of bFGF. bFGF treatment on St 10.5 ectoderm did not induce muscle actin or collagen type II mesoderm, and repressed XAG-1 expression. EF-1a is a loading control. (B) When ectoderm is treated at stage 11, En-2 is induced by a wide range of doses, with 2 ng/ml being the minimal dose.
Image published in: Lamb TM and Harland RM (1995)
Copyright © 1995. Image reproduced with permission of the publisher and the copyright holder. This is an Open Access article distributed under the terms of the Creative Commons Attribution License.
Permanent Image Page
Printer Friendly View
XB-IMG-154781